Filing Impact
Filing Sentiment
Form Type
4
Shattuck Labs, Inc.
Aug 26, 2025
Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors
Aug 21, 2025
Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease
Aug 14, 2025
Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Sep 2, 2025
[SCHEDULE 13D] Shattuck Labs, Inc. SEC Filing
72.33M
40.71M
14.36%
59.03%
0.9%
Biotechnology
Pharmaceutical Preparations
United States
AUSTIN